Complex Case Spotlight
Having deferred radical cystectomy for years, a patient with a long history of recurrent high-risk non-muscle-invasive bladder cancer (NMIBC), who became unresponsive to bacillus Calmette-Guérin (BCG), responded well after ultimately undergoing surgery and urinary diversion. According to Gary D. Steinberg, MD, director of the Goldstein Urology Bladder Cancer Program at Perlmutter Cancer Center, the case is representative of a common clinical conundrum—is it safe to defer or avoid radical cystectomy for BCG-unresponsive high-risk disease?
View Case Study
Recent Articles

Systematic review ties plant-based regimen to reduced prostate cancer risk, improved outcomes, and overall health.

Chief Quality Officer Ilseung Cho, MD, discusses the deeper meaning and impact behind NYU Langone’s top accolades for care quality and safety.

NYU Langone Health: A Leader in Urology
Ranked #10 in Urology
Top 10 in NIH funding (Source: Blue Ridge)
Pioneers in MRI to evaluate prostate cancer
Subscribe for Updates from NYU Langone
Sign up for Physician Focus emails for practice-changing news and perspectives from our experts at NYU Langone Health.
Select Your Interests
Copyright © 2022 NYU Langone Health, All rights reserved.
NYU Langone Health
One Park Avenue, 5th Floor
New York, NY 10016